Chronic cough, defined as a cough lasting more than eight weeks, is a common yet perplexing clinical challenge. Despite its prevalence, the underlying etiologies often remain elusive, leading to diagnostic dilemmas and therapeutic frustrations. This article aims to provide a comprehensive approach to diagnosing and managing chronic cough in clinical practice.
Chronic cough is usually a symptom of an underlying condition such as asthma, gastroesophageal reflux disease (GERD), or upper airway cough syndrome (UACS). Other less common causes include bronchiectasis, chronic obstructive pulmonary disease (COPD), and lung cancer. The pathophysiology of chronic cough involves a complex interplay between the cough reflex pathway and various inflammatory, mechanical, or chemical stimuli.
A thorough history and physical examination are paramount in the evaluation of chronic cough. Special attention should be given to the patient's medication history, as drugs like angiotensin-converting enzyme (ACE) inhibitors can induce cough. Diagnostic tests such as spirometry, chest X-ray, and bronchoscopy can be useful depending on the suspected underlying cause. In some cases, a trial of treatment may be warranted to confirm the diagnosis.
The management of chronic cough should be targeted at the underlying cause. This may involve pharmacological treatment, such as inhaled corticosteroids for asthma or proton pump inhibitors for GERD. Non-pharmacological interventions, such as lifestyle modifications and pulmonary rehabilitation, can also be beneficial. Refractory cases may require referral to a specialist for further evaluation and management.
Chronic cough is a multifaceted clinical problem that requires a comprehensive and individualized approach. By understanding the potential etiologies, employing a systematic diagnostic process, and tailoring the management plan to the underlying cause, clinicians can effectively diagnose and manage chronic cough, thereby improving patient outcomes and quality of life.
1.
Mosunetuzumab in Follicular Lymphoma: Durable Responses and Manageable Safety
2.
As EGFR internalization is decreased, BUB1 controls EGFR signaling.
3.
Getting Lung Cancer Screening Staff Involved Improved Tobacco Cessation
4.
Low Income, Education Tied to Depression in Older Adults
5.
In Higher-Risk MDS, CMML, All-Oral Therapy Has Promise.
1.
Bridging Disciplines: Medical Oncology vs Surgical Oncology in the Era of Multidisciplinary Cancer Care
2.
Next-Gen CAR Cell Therapies in Oncology: Frontiers in Solid Tumors & Hematologic Malignancies
3.
Next-Generation Sequencing in Oncology: Unlocking the Future of Precision Medicine
4.
Unlocking the Key to Treating Lymphoma: New Innovations in Cancer Research
5.
Personalizing Cancer Care: Microbiome Advances, Challenges, and Future Directions
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part VI
2.
Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part IV
4.
Managing CNS diseases at the point of diagnosis in ALK + NSCLC
5.
Navigating the Complexities of Ph Negative ALL - Part XV
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation